• Sigyn Therapeutics has designed a pipeline of medical technologies to improve cancer treatment outcomes by reducing the circulating presence of bloodstream particles that decoy or block the intended delivery of cancer therapies. At present, less than 2% of therapeutic antibodies and chemotherapy doses administered to cancer patients are delivered to tumor cell targets
• The company has also created a medical technology to reduce the circulating presence of off-target chemotherapy from the bloodstream to reduce patient toxicity and organ damage
• The company’s lead therapeutic candidate addresses life-threatening conditions that are pathogen-induced and not addressed with drug therapies

Sigyn Therapeutics (OTCQB: SIGYD, SIGY), a development-stage medical technology company creates therapeutic candidates with two prerequisites in mind: 1) they must offer to overcome a clearly defined limitation in global health, and 2) their successful clinical advancement would provide a potential competitive advantage within an established therapeutic industry segment.

The company’s therapeutic candidates include:

• Sigyn Therapy(TM) – to treat pathogen-associated conditions that are not addressed with FDA-approved drugs
• ImmunePrep(TM) – a platform to enhance the performance of therapeutic antibodies to treat cancer
• ChemoPrep(TM) – to improve the delivery of cancer chemotherapies
• ChemoPure(TM) – to reduce the post-treatment toxicity of chemotherapy

Sigyn Therapy(TM) is a novel blood purification technology being advanced to treat pathogen-associated inflammatory disorders. To date, in vitro studies have demonstrated the ability of Sigyn Therapy(TM) to reduce the circulating prevalence of twelve different pathogen and inflammatory disease targets from human blood plasma.  Based on these outcomes, candidate treatment indications include community-acquired pneumonia, endotoxemia, drug resistant viral and bacterial infections, and sepsis, the leading cause of hospital deaths in the United States.  First-in-human feasibility studies of Sigyn Therapy(TM) plan to enroll end-stage renal disease (“ESRD”) patients with endotoxemia and concurrent inflammation, which are highly prevalent and associated with increased mortality in the ESRD population.

ImmunePrep(TM) is a development-stage commercialization platform to enhance and extend the performance of immunotherapeutic antibodies, which account for nine of the top 15 best-selling cancer treatment drugs. ChemoPrep(TM) is designed to optimize the delivery of chemotherapy, the most commonly administered drug to treat cancer, while ChemoPure(TM) extracts off-target chemotherapy from the bloodstream to reduce patient toxicity.

Sigyn Therapeutics CEO, James A. Joyce, on the inspiration for ChemoPrep and ChemoPure stated, “They were designed to improve cancer patient outcomes and improve quality of life based on the unfortunate reality that a vast majority of chemotherapy is not delivered to intended tumor cell targets and off-target chemotherapy remaining in the bloodstream is more likely to contribute to patient toxicity versus therapeutic benefit.”

For more information, visit the company’s website at www.SigynTherapeutics.com.

NOTE TO INVESTORS: The latest news and updates relating to SIGY are available in the company’s newsroom at https://ibn.fm/SIGY

• Arizona-based SenesTech Inc., is dramatically improving pest management technicians’ toolbox with its patent-pending Evolve(R) soft bait birth control product for rodents
• SenesTech’s Evolve(R) product joins the liquid ContraPest(TM) product in providing a non-lethal solutions to reducing rodent populations
• The company’s CEO and CFO recently appeared virtually at the Lytham Partners 2024 Investor Select Conference, participating in a fireside chat interview and meeting one-on-one with potential investors
• SenesTech also recently announced increased distribution of its product in partnership with Poppe Enterprises LLC, — a company that serves the grain management market in Nebraska, South Dakota, North Dakota, Kansas, Wyoming, Iowa, and Colorado

The chief officers of enterprising rodent control company SenesTech (NASDAQ: SNES) participated in a fireside chat interview detailing the company’s operations and also met with potential investors one-on-one at this month’s virtual Lytham Partners 2024 Investor Select Conference.

CEO Joel Fruendt and CFO Tom Chesterman enjoyed the opportunity to discuss the breakout success of its non-lethal Evolve(TM) Soft Bait product following on the heels of successful implementation of its original liquid bait formulation ContraPest(R), which, like Evolve(TM), is designed to reduce rat populations by administering an ingestible birth control product that keeps rodents from proliferating.

The webcast of the Feb. 1 fireside interview is available on the company’s website at https://ibn.fm/q1K6P.

The patent-pending Evolve(TM) soft bait has a sausage-like appearance and poses little or no risk to human health or the environment — a significant advantage over poisons used to kill rats. SenesTech’s products are the first, and still the only, such rat contraceptives registered with the U.S. Environmental Protection Agency (“EPA”) that target both male and female rats.

And, while trapping and poisons may eliminate rodents quickly, leaving their carcasses to be cleaned up as evidence of their effectiveness, even a single breeding pair of surviving rodents can lead quickly to a new generation of up to 15,000 offspring after a single year, according to Fruendt.

The company recommends using its Birth Control for Rats(TM) products in tandem with other rodent control products, since rats that consume Evolve(TM) or ContraPest(R) will continue to live out their life cycles for months, just without adding new generations of pups. But SenesTech’s products can be used on their own if preferred.

“The most (effective approach) is combining the elements of integrated pest management, and having them work together and support each other. We have plenty of evidence that outcomes are improved over the baseline when ContraPest(R) is added to an integrated pest management program but, given enough time, the product will work (by) itself,” Fruendt said in a Q&A forum featured on SenesTech’s YouTube channel (https://ibn.fm/SIM5A).

The company’s reach is expanding globally — in addition to outlets across the United States, government entities in South Africa, the Maldives and, last month, the United Arab Emirates (“UAE”) market have entered agreements with the company.

On Jan. 29, SenesTech announced a distribution agreement with Poppe Enterprises LLC, which serves the grain management market in Nebraska, South Dakota, North Dakota, Kansas, Wyoming, Iowa, and Colorado (https://ibn.fm/CB2aQ).

“Grain storage operations have unique challenges when it comes to rodent pest control. Poisons are highly regulated and are tricky to use without contamination, and traps are expensive and time-consuming to maintain,” Fruendt stated. “Poppe Enterprises has a keen focus on innovation, safety, and sustainability, and a strong reputation in this substantial market.”

For more information, visit the company’s website at www.SenesTech.com.

NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://ibn.fm/SNES

• SuperCom, a global provider of digital identity and electronic monitoring (“EM”) solutions, just announced a new project in the tracking sector with a renowned Canadian industry partner
• The initial phase of the project is set to launch in the first quarter of the 2024 calendar year, with significant potential for expansion in both scale and scope
• The project will include the transition from RF-based tracking technology to new GPS tech using SuperCom’s PureOne devices

SuperCom (NASDAQ: SPCB), a global leading provider of digital identity and electronic monitoring solutions and services to governments and institutions, just announced a new project with a renowned Canadian industry partner in the tracking solutions sector. This marks an impressive start to the new year and a healthy addition to SuperCom’s current client and project portfolio, comprising governments and notable institutions in over 10 countries (https://ibn.fm/pmZRq).

The new project comes in the wake of the growing realization that offender monitoring solutions reduce recidivism among offenders. In a study conducted by Jenny Williams and Don Weatherburn, it was established that electronic monitoring for offenders was associated with a 25% reduction in the likelihood of reoffending compared to serving time in prison. This is significant, especially since the average rate of reoffending within 24 months of free time is 58% for those who serve a prison sentence (https://ibn.fm/ScXzE).

SuperCom has been bullish on its electronic offender monitoring solutions. Having been keen on developing and improving it over the years, the Finnish government has adopted it, with positive results achieved from its usage. In addition, it has seen the products distributed in the U.S. market, an indicator of the growing demand and the overall value they offer. This new project in Canada marks a new chapter in the company’s long-standing collaboration with this partner. It will see the transition from successful collaboration for providing RF-based tracking technology to embracing new GPS technologies using SuperCom’s state-of-the-art PureOne devices.

“We’re excited about this new project in Canada,” noted Ordan Trabelsi, CEO and President of SuperCom. “This project not only strengthens our relationship with a valued partner but also highlights our commitment to innovation and adapting to market needs,” he added.

The project’s initial phase is set to launch in the first quarter of the 2024 calendar year, with significant potential for expansion in both scale and scope. For SuperCom, this collaboration is a testament to its enduring partnerships and capacity for future growth. It is also a testament to its ability to adapt to the evolving needs of its clients.

“We are proud to see the trust and confidence our partner has placed in us and our innovative tracking solutions,” noted Mr. Trabelsi. “This project exemplifies our dedication to delivering cutting-edge technology and reinforces our position as a leader in the electronic monitoring industry,” he concluded.

For more information, visit the company’s website at www.SuperCom.com.

NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB

• GEMXX recently announced insights into the burgeoning jewelry and colored gemstones markets in India
• The jewelry market in India is expected to grow by US$21.54 billion between 2023 and 2027, while the colored gemstones market is projected to reach $1.9 billion by 2033 from an estimated $707.8 million in 2024
• GEMXX, a leading producer of top-quality finished Ammolite, anticipates that this rare gemstone has the potential to attract a significant portion of buyers in India seeking something innovative or distinct from conventional colored gemstones
• The company is positioned to capitalize on the growing trend in the colored gemstones market, with its unmatched mine-to-market hold on high-quality Ammolite supplies, by offering a wide array of Ammolite products to cater to the evolving preferences of consumers in India

India’s colored gemstone industry has rebounded, witnessing a resurgence in demand after taking a hit during the pandemic in 2020. Multiple reasons have been advanced to explain the recovery, including the growing impact of social media, the middle-class population’s growing desire for a more luxurious lifestyle, improving standards of living, the traditional appreciation of jewelry as a store of wealth and a secure asset, plus general aesthetic reasons (https://ibn.fm/j4vO2).

“Beyond mere aesthetics, gemstones and gold in India hold a distinct significance for a substantial portion of the population, believed to possess almost divine powers. The demand for colored gemstones is also on the rise, driven by their perceived Vedic properties, making them more than just precious stones but also carriers of sentimental and astrological value,” wrote GEMXX (OTC: GEMZ) in a Jan. 31 press release announcing its insights into the burgeoning jewelry and colored gemstone markets in India (https://ibn.fm/lid3r).

A leading mine-to-market company, GEMXX controls every stage of its operations, from gold and gemstone extraction to jewelry production and worldwide distribution. The company is currently focused on mining and producing jewelry out of gold, a traditional safe-haven asset, and Ammolite, a rare gemstone with iridescent properties.

GEMXX had previously projected a promising future for gold, a commodity it forecasts will reach new highs in the coming 24 months (https://ibn.fm/C24Fq). In a more recent announcement, the company provided a similarly positive outlook covering India’s burgeoning markets for colored gemstones, of which Ammolite is part, and jewelry.

In the press release, GEMXX highlighted recent industry forecasts, which anticipate that the jewelry market in India will surge by US$21.54 billion between 2023 and 2027, representing an impressive CAGR of 5.54%. This growth, GEMXX holds, is positioning India as a key player in the global jewelry arena. The company also singled out the colored gemstones market in India, which analysts expect to reach $707.8 million in 2024 and US$1.9 billion by 2033, marking a robust 10.5% CAGR between 2023 and 2033.

“This industry forecast pinpointing the increase in demand for colored gemstones and gold allows investors a safe haven for investing in a company backed by gemstones and gold rather than a sometimes-volatile technology stock,” said Jay Maull, CEO of GEMXX Corp. “The growth rate of the colored gemstone market in India is surpassing the overall growth rate of the jewelry market in India by 2.1%.”

According to Maull, Ammolite, a relatively recent addition to the Indian colored gemstone market, has the potential to attract a significant portion of buyers seeking something innovative or distinct from conventional colored gemstones. Against this backdrop, GEMXX is positioned to take advantage of this growing trend by offering a wide array of ammolite products to cater to the evolving preferences of the Indian market.

“GEMXX stands out as the leading producer of top-quality finished Ammolite, surpassing all other competitors in terms of quality and production capacity,” the company says on its website (https://ibn.fm/nVFGt). These unique capabilities are expected to enable GEMXX to continue to innovate and provide unique gemstone options that resonate with not only the cultural practices but also the spiritual beliefs of consumers in India.

Those interested in participating through Reg A financing are encouraged to visit the company’s investor page (https://ibn.fm/Wj0Ci) or contact company officials for more information (ir@gemxx.com – 702-930-1815).

For more information, visit the company’s website at www.GEMXX.com/investors.

NOTE TO INVESTORS: The latest news and updates relating to GEMZ are available in the company’s newsroom at https://ibn.fm/GEMZ

• Utah-based Diamond Lake Minerals is developing its vision of an umbrella parent company that not only holds a variety of industry-crossing subsidiaries, but that also serves as a gateway for cautious investors looking to dip a toe into digital assets
• The company’s vertically integrated portfolio will include holdings that are infused with security token offerings registered with the U.S. Securities and Exchange Commission
• Diamond Lake views its digital asset-in-a-real world asset gateway as a hedge against market volatility, especially for real estate properties that may be over-leveraged and struggling to stay afloat while seeking favorable lending terms
• A recent spate of bad debt concerns in the commercial real estate arena has raised warnings about bank exposure and a possible run against uninsured financiers

Recent concerns about a global wave of commercial real estate loan defaults, described as potentially the worst crisis for the sector since the 2008 bursting of the global financial bubble, is leading banks to proactively assure investors about their ability to absorb potential losses, while investors scrutinize loan books for signs of insecurity (https://ibn.fm/v5SpF).

As investors worry, multi-strategy operating company Diamond Lake Minerals (OTC: DLMI) is pursuing a course that offers investors regulatory oversight in the digital asset market and a potential solution to “underwater” real estate property owners that could offset volatility in the market.

Diamond Lake CEO Brian J. Esposito commented on the company’s solution for helping people generate wealth from both digital and traditional securities in a Jan. 31 interview with Proactive Investors (https://ibn.fm/2BXza), highlighting the role real estate may play in the growth of fractional security token offering (“STO”) ownership of real assets.

“A lot of these properties are highly leveraged — they can be overvalued. And they’re sitting on balance sheets somewhere that have a potential risk factor, especially for banks that are holding this paper,” Esposito said. “It’s very hard to create liquidity for those building holders, or those property holders. So if you were to take that building that you couldn’t get rebank financing … on that property, but it does have the ability to earn and create value, well then you can open it up to millions of people around the world through a proper security token offering and (do) it under the right rules and regulations, where now you have all kinds of potential liquidity and capital coming in.”

Esposito said offsetting market volatility by opening commercial properties up to fractional ownership is Diamond Lake’s approach to creating a “giant funnel of liquidity and access to capital that was never able to be accessed before.”

The company is saying, “Hey, I don’t want to see the real estate market collapse, … because of all those assets in the trillions … that’s on balance sheets around the world,” he added. “If that starts to crumble, it hurts everybody — it hurts the local economy, it hurts the stock market.”

Diamond Lake is creating a powerful parent umbrella company with quality, industry-agnostic assets, and imbuing those vertically integrated subsidiaries with U.S. Securities and Exchange Commission (“SEC”)-registered STOs via the regulated security token exchange INX.

Diamond Lake’s gateway therefore is not only to the real asset holdings in sectors ranging from entertainment to real estate to health care and medicine, but also to the emerging market sector that digital assets comprise.

“We want to always create responsible business transactions. We like to do these things with seasoned entrepreneurs and professionals who’ve got great accounting and regulatory and compliance,” Esposito said. “Anything that’s a really good asset for our balance sheet and anything that we can create great profitability and returns for, that’s what we want under our DLMI umbrella.”

In addition, for information on the company’s security token SEC regulated exchange partner INX, and the development of the INX Way, visit https://www.inx.co/inx-ebook/. This free security token bible, written with the SEC on the rollout of security tokens and the future of digital assets, will greatly deepen your understanding of security tokens.

For more information, visit the company’s website at www.DiamondLakeMinerals.com or LinkedIn page at www.LinkedIn.com/company/Diamond-Lake-Minerals/.

NOTE TO INVESTORS: The latest news and updates relating to DLMI are available in the company’s newsroom at https://ibn.fm/DLMI

• The Activist Investor Conference will take place on March 21, 2024, at 237 Park Avenue, one of Manhattan’s premiere meeting venues
• The 14th annual edition of the conference features investors, corporate board members and governance experts, advisory firms, proxy solicitors and finance professionals who will delve into the latest trends within shareholder activism
• This year’s conference features a number of keynote presentations by experts in the field, including Patrice Bonfiglio, Sean Donohue, and Jon Feldman

Shareholder activism emerged in the 1970s and 1980s as a tool to drive the process of price formation, improve corporate governance and defend minority shareholder interests. Today, in a market environment characterized by a surge in the number of passive investors and a reduction in the diversity of research and market participants, the importance of shareholder activism may be greater than ever.

Corporate engagement and shareholder activism has become increasingly crucial within the context of modern financial markets.

With over 20 years of experience and having hosted over 200 conferences, seminars and webcasts on a variety of financial topics, DealFlow Events is gearing up to host the upcoming Activist Investor Conference 2024 on March 21, 2024 in New York City. Now in its 14th year, the Activist Investor Conference delivers an invaluable forum for discussion of governance-related issues by savvy finance professionals seeking to improve the fortunes of the companies in which they’ve invested.

Covering a wide range of topics, including ‘Value Investing’, ‘Trending Legal Issues Facing Shareholder Activism’, ‘How the Lone Dissident can Prevail’ and the ‘Impact of corporate relations with shareholders on an activist campaign’, the conference presents a slate of keynote presentations throughout the day. Speakers include Patrice Bonfiglio, President at Sarissa Capital; Sean Donohue, Co-Chair of Shareholder Activism and Takeover Defense at Paul Hastings LLP; Jon Feldman, Partner at Goodmans; Adam Kommel, Shareholder Activism Development Lead at Bloomberg LP; and Michael Levin, Founder of The Activist Investor, among several other experts in the field.

Conference attendees will be in an enviable position to hear key insights into the world of activist investing. Ranging from understanding the evolution of shareholder and management rights over time, to learning about board size, short attacks and activist strategy, investors will learn about what really matters within activist investing today as well as what to expect in the future.

For additional details about the Activist Investor Conference, including registration, visit: https://www.activistinvestorconference.com.

• SOBRsafe recently published three case studies that empirically demonstrate the performance of its alcohol screening technology, SOBRcheck(TM), based on customer data, experiences, and results
• SOBRcheck can be used as a safe, convenient, and fast replacement for cumbersome and unhygienic breathalyzers 
• One case study shows that SOBRcheck enabled TerraTech to achieve a 100% pass rate per week against an estimated industry average weekly violator rate of between 60% and 70%
• By deploying SOBRcheck, Big Horn County has been able to provide cost-effective alcohol monitoring services for more than 100 community members, while Alternatives Inc. has achieved 4x faster throughput at check-in/check-out
• SOBRsafe CEO recently provided a comprehensive update on the company in a fireside chat video

A disruptive company leveraging advanced alcohol detection approaches and technologies, SOBRsafe (NASDAQ: SOBR) is a provider of next-generation touch-based alcohol screening, detection, and monitoring solutions, as well as real-time reporting software. Among these revolutionary solutions is SOBRcheck(TM).

A stationary identification and alcohol screening/monitoring technology launched in 2021, SOBRcheck detects and instantaneously reports the presence of alcohol emitted through the pores of a fingertip. It is equipped with a biometric identifier that automatically confirms the user’s identity and hardcodes this identification information, as well as the date and time of the screening, into the automatically generated reports, thus boosting reliability.

SOBRcheck can be used at the entry points of job sites, as TerraTech Services, a national leader in oilfield services and logistics, has done since November 2022, following a successful pilot program. In this pilot program, TerraTech worked with SOBRsafe to deploy the SOBRcheck platform at the points of entry of two of its 16 sites.

The results were remarkable, with TerraTech experiencing “tremendous success,” as a Health, Safety, and Environment Manager at the company put it. TerraTech achieved 100% compliance from employees at both pilot sites within a short period, so much so that after a month of daily testing, the company was confident of SOBRcheck’s effectiveness and subsequently worked with SOBRsafe to install the SOBRcheck devices at the remaining 14 sites.

This larger-scale deployment result was as impactful as the first, with one location witnessing a remarkable 100% decrease in alcohol-positive results within a two-week period. Overall, TerraTech, which screens employees for alcohol three times a day, had logged over 80,000 scans into the SOBRsafe portal as of December 31, 2023, achieving an effective 100% pass rate per week. In contrast, TerraTech estimates that the industry average weekly violator rate stands at 60-70%.

SOBRcheck can also be deployed to replace traditional breathalyzer tests, which require dedicated staff – because they have to be manually administered – and are expensive, cumbersome, time-consuming, and unhygienic. For instance, Big Horn, Montana’s 6th largest county in landmass, which previously used traditional breathalyzer tests for its 24/7 Sobriety Program, turned to SOBRsafe in July 2023, initially deploying the SOBRcheck technology in two locations within the County building.

Since deployment, the screening has followed – and still follows – an unstaffed testing procedure in which each participant simply completes their alcohol screen in about 10 seconds. This marks an improvement from the past when it could take hours for County staff to process a group of individuals. In conjunction with SOBRsafe, Big Horn County has created an efficient, cost-effective program for court-mandated, passive alcohol screening outside of major metro areas. The program is not only hygienic and convenient, but it also improves safety, reduces costs, and enhances accountability and accessibility. As of December 2023, for example, it had achieved a 92% total pass rate, up from 67% in July (https://ibn.fm/4GAe5).

“In providing cost-effective monitoring services for more than 100 community members, SOBRcheck has been a big win for our county staff, taxpayers, and participants,” the second case study quotes Big Horn County Misdemeanor Probation and Pre-Trial Services Officer as saying. “Both participants and our staff are given back hours in their days to be more productive. I believe this will also lead to more successful results for all those in court-mandated programs, as it is no longer cost-prohibitive to participate.”

On its part, Alternatives Inc., a leader in community corrections and re-entry strategies, installed SOBRcheck devices at the Alpha House, a men’s pre-release center, and Passages, a residential program for women comprising of a pre-release center, an assessment center, and a drug and alcohol treatment program. SOBRcheck delivers in 10 seconds what the observed screening procedure using a traditional breathalyzer would deliver in 45 seconds, with the high number of screens compounding the time savings.

“Across 2,073 scans, it would have taken the Alternatives team approximately 25 hours via their observed breathalyzer process versus less than six hours with SOBRcheck – up to 4x faster throughput [at check-in/check-out],” explains the third case study (https://ibn.fm/mErml). Thus, SOBRsafe’s revolutionary device is much faster than the traditional test.

SOBRsafe has also recently provided a comprehensive video update on the company from Chairman and CEO Dave Gandini (https://ibn.fm/mN0MV). In the video, Gandini discussed the company’s suite of solutions, target markets (including justice and behavioral health), out-licensing prospects, integration opportunities, supply chain, product fulfillment, customer service, a digital and social media initiative to drive online SOBRsure sales at www.SOBRstore.com, and more. To watch the video, please visit https://ibn.fm/DSidn (registration required).

For more information, visit the company’s website at www.SOBRsafe.com.

NOTE TO INVESTORS: The latest news and updates relating to SOBR are available in the company’s newsroom at https://ibn.fm/SOBR

• Lexaria, a global innovator in drug delivery platforms to enhance bioavailability, announced recently that it will focus on GLP-1 applications for diabetes and weight loss for the 2024 calendar year
• Chris Bunka, Lexaria’s CEO, has expressed his confidence in the company’s direction, reiterating the intention to demonstrate the superior performance of GLP-1 drugs processed with its patented DehydraTECH(TM) technology
• The company looks to build on the success of the early-stage results achieved in 2023, and looks to embark on two human pilot studies, a multi-arm 12-week animal chronic study, a human chronic weight-loss and diabetes study, as well as a multi-month stability testing of DehydraTECH GLP-1

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced its 2024 R&D plans, with emphasis on GLP-1 investigations. GLP-1 agonists (glucagon-like peptide 1) is a class of drugs used for diabetes and weight loss.

This comes hot on the heels of a successful, active year of R&D in 2023, a year that saw significant strides in developing its patented DehydraTECH(TM) technology including its new foray into GLP-1 drugs. Chris Bunka, Lexaria’s CEO, expressed his confidence and overall optimism in the company’s new direction, reiterating the company’s intention to demonstrate the superior pharmacokinetics and safety/efficacy performance of GLP-1 drugs when formulated and processed with DehydraTECH (https://ibn.fm/92pzS).

In 2023, DehydraTECH showed positive results in its 8-week study that involved 32 diabetic rodents. The study showed that DehydraTECH-CBD lowered triglyceride levels and body weight differential over the eight weeks, positive results that would also be replicated in its other studies including, but not limited to, hypertension, human hormones, and the overall reduced risk of oral nicotine. This laid the groundwork for Lexaria to explore a new class of molecules it had never worked on before, ultimately quietly launching its top-priority and unpublicized early-stage work program – GLP-1- for weight loss and diabetes control.

In the words of Mr. Bunka, this was a “high-risk program,” mainly because this class of drugs is considered “large molecules,” yet all of Lexaria’s previous investigations were concentrated on “small molecules.” However, by the end of November and early January 2024, the company reported positive interim and final human pilot study results using a single semaglutide dose of a Rybelsus(R) tablet to a matching dose from Rybelsus(R) that had been compound formulated in capsule form using DehydraTECH processing technology enhancements. This was a massive milestone for Lexaria, with Bunka describing the results as “surprising.” Of note was that DehydraTECH processing delivered a statistically-significant higher proportion of the semaglutide and did so more quickly, ultimately having a statistically-significant impact on blood sugar.

GLP-1 drugs have been receiving rising interest recently. Having received FDA approvals as recently as 2021 and 2022, mainly given its health benefits and potential market size, Lexaria understands that this could be the next best thing, hence its focus on this drug class.

“Our R&D plans for 2024 are very tightly focused and will be concentrated mainly on GLP-1 investigations,” noted Mr. Bunka.

“Given the overwhelming interest in the GLP-1 sector, this will be a main focus. We are not at this time planning additional 2024 research in the antiviral, nicotine, or PDE5 sectors. We have solid early-stage data in each of those areas that will allow us to build upon those at the right time,” he added.

Mr. Bunka has reiterated that 2024 will be the year that Lexaria’s hard work will prove its worth. He looks to follow up on the positive early-stage results achieved in 2023, even as it embarks on two human pilot studies, a multi-arm 12-week animal chronic study, a human chronic weight-loss and diabetes study, as well as a multi-month stability testing of DehydraTECH GLP-1. Mr. Bunka is confident that its focus on GLP-1 drugs will yield this outcome.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• The CDC estimates that the prevalence of ASD in the United States is 1 in 36 children, with no approved pharmacologic treatments targeting the cause and symptoms
• PaxMedica is developing novel anti-purinergic therapies for the treatment of ASD and other serious conditions with intractable neurologic symptoms, and is on a promising path to address the unmet medical needs and bring hope to millions
• Company CEO Howard Weisman recently shared insights into PaxMedica’s achievements and advancements in a Fireside Chat video, underscoring the company’s commitment to groundbreaking therapies and transformative solutions

The prevalence of autism spectrum disorder (“ASD”) in the United States has risen to approximately 1 in 36 children, according to the Centers for Disease Control and Prevention (“CDC”). There are currently no approved pharmacologic treatments that target the causes and symptoms of ASD – the only treatment available on the market addresses symptoms of the condition rather than targeting the pathophysiology itself (https://ibn.fm/2adEF).

ASD is characterized by extreme versions of the processes governing the ability to focus attention and filter out sensory input. These processes often bring a wide range of special abilities, including the ability to hyperfocus on specific tasks, but they make normal everyday interactions and activities more challenging. These challenges don’t only affect those with ASD but the family and friends around them.

PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company focused on the development of novel anti-purinergic therapies (“APTs”) for the treatment of ASD and other serious conditions with intractable neurologic symptoms, is on a promising path to address the unmet medical needs and bring hope to millions. The company’s CEO, Howard Weisman, recently shared insights into PaxMedica’s recent achievements and advancements in a Fireside Chat video, underscoring the company’s commitment to groundbreaking therapies and transformative solutions. The full video can be found on the company’s website or through PaxMedica’s YouTube channel (https://ibn.fm/G743s).

Mr. Weisman discussed the following key attributes during the video:

• A regulatory update with insights from the recent FDA Type-B meeting on October 25, 2023, shed light on the regulatory pathway for PAX-101 for HAT
• The financial boost of a successful $7 million public offering strengthened PaxMedica’s balance sheet and provided a financial platform for production and clinical trial initiatives
• The acquisition of suramin research assets from Rediscovery Life Sciences potentially expediting NDA submission for PAX-101
• A company update on clinical trial progress, with insights into future ASD trials
• Insight into PaxMedica’s business strategy to emphasize efficiency, production milestones, and key partnerships with organizations like Vox Nova
• The future vision of the company includes NDA plans for PAX-101 and potential advancements in autism treatment

The ASD therapeutics market was valued at $1.93 billion in 2022 and is expected to reach $3.42 billion by 2030, growing at a CAGR of 7.9%. The growing prevalence of this disease globally, in addition to the rising awareness about ASD, including available options and treatments, are key factors driving the market (https://ibn.fm/PvYf9). These estimates do not factor into the potential impact of treatments designed to address the core symptoms of ASD but provide insight into the market interest in therapeutics for ASD.

PaxMedica intends to continue into 2024 with the momentum it has gained with its achievements during the past year. The company is building a robust product pipeline to allow people with ASD to successfully integrate their behavior with others and improve their lives. Its lead programs, PAX-101 and PAX-102, utilize the company’s proprietary source of suramin sodium, a broadly acting APT known for over 100 years.

For more information, visit the company’s website at www.PaxMedica.com.

NOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at https://ibn.fm/PXMD

• Mullen debuted its FIVE RS at this year’s CES show in Las Vegas
• Several car and auto publications reported on the unveiling of the new model
• Mullen anticipates beginning production of the FIVE RS in late 2025, with sales commencing in mid-2026

For the first time ever, Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, exhibited its line of commercial and consumer EVs at the Consumer Electronics Show(R) (“CES”) in Las Vegas. In addition to displaying its line of vehicles, the company also debuted its high-performance EV crossover, the Mullen FIVE RS; the world debut of the new vehicle garnered coverage in several car and auto magazines.

In its coverage, CarScoops notes that the Mullen FIVE RS has an intriguing design, big performance claims and a production date set for late 2025 (https://ibn.fm/nWYyZ). The article pointed out key features of Mullen’s latest offering, including its fast-charging capabilities, integrated infotainment system, artificial intelligence-based personal assistant called Persona, facial recognition technology and level 2+ driver assistance tech.

“Although seeing EVs with impressive performance figures is nothing new, it’s still a little surprising to encounter an electric crossover making promises of this magnitude,” the article stated. “Equipped with dual motors residing at the front and rear axles, the FIVE RS boasts a staggering 1,000 hp (746 kW/1,014 PS) and over 850 lb-ft (1,151 Nm) at its disposal, with Mullen claiming that it will be able to reach 60 mph (96 km/h) in under two seconds. Even more impressively, the automaker promises that its crossover will be capable of reaching a top speed of 200 mph (322 km/h) or even higher. . . . Mullen anticipates commencing production of the FIVE RS in late 2025, with sales set to commence in mid-2026. Subsequent versions of the SUV, including the $55,000 entry-level variant (originally slated for late last year), will follow in due course.”

AutoCar magazine noted that the electric super-crossover may be a rival to the Tesla Model X Plaid and Lucid Air Dream Edition (https://ibn.fm/SRtew). The article noted that Mullen CEO David Michery “gave few technical details away at the car’s unveiling but did confirm that the RS features a twin-motor, four-wheel-drive powertrain and 800V charging architecture that is said to allow for a 0–80% top-up in just 21 minutes.”

The article also reported that the car will be fitted with six- and four-piston Brembo brake calipers clamping carbon-ceramic discs, an ultra-performance race-track mode for maximum power and more engaging steering, and an AI-powered voice assistant with facial-recognition technology. The article quoted Michery as saying that “from the inception of Mullen, it has been my mission to bring an ultra-high-performance EV to market. The FIVE RS is intended to be one of the fastest vehicles on the planet, competing with some of the best and most well-known and regarded automotive marques.”

Road Track reported that the sporty new model is “ready to challenge Tesla and Lucid in the performance EV space. . . . Known as the Mullen FIVE RS, this electric crossover promises to bring over 1000 hp and a sub-2.0-second 0-60 mph sprint” (https://ibn.fm/OtB4S).

Calling the FIVE RS “a hotter variant of the brand’s FIVE SUV,” the article noted that the EV is powered by a 100-kWh battery pack that feeds a pair of electric motors to provide all-wheel drive and more than 1000 horsepower and 850-pound feet of torque. The design includes a two-speed sequential transmission sitting with either motor, which Mullen says will help the sleek SUV hit 60 mph in less than two seconds. In addition, the article reported that a set of either 21- or 22-inch wheels will cover carbon Brembo brakes at all four corners and will come wrapped in performance rubber. Mullen is working to reach 300 miles per charge, the article stated.

The Consumer Technology Association, which owns and produces the consumer technology trade show, expected 130,000 attendees and more than 4,000 exhibitors at this year’s event. CES is the most powerful tech event in the world, has established itself as the proving ground for breakthrough technologies and global innovators, and is the only trade show that showcases the entire tech landscape at one event (https://ibn.fm/4WOWp).

During CES, Mullen displayed the following vehicles: the Mullen ONE Class 1 Commercial EV Cargo Van; the Mullen THREE Class 3 Commercial Low Cab Forward; the Box Truck (ToughLite Upfit); the Service Truck (Phenix Truck Bodies Upfit); the Bollinger B1 Electric SUV; the Bollinger B2 Electric Pick Up; and the Bollinger B4 Class 4 Chassis Cab and Box Truck. In addition, on Jan. 9, at 11 a.m. PT, the company unveiled the Mullen FIVE RS, a high-performance variant of its flagship EV crossover (https://ibn.fm/geHrv).

Mullen Automotive is a Southern California-based automotive company building the next generation of electric vehicles in its two United States-based manufacturing and assembly plants. Mullen’s EV development portfolio includes the Mullen FIVE Crossover and FIVE RS High-Performance Sport Crossover EVs, Mullen GT and GTRS EV Supercars, Mullen PowerUP Mobile EV Charging Truck, Mullen-GO Commercial Urban Delivery EV, Mullen Commercial Class 1-3 EVs, and Bollinger Motors, which features the B1 and B2 electric SUV trucks and Class 4-6 commercial offerings. On Sept. 7, 2022, Bollinger Motors became a majority-owned EV truck company of Mullen Automotive, and on Dec. 1, 2022, Mullen closed on the acquisition of all Electric Last Mile Solutions (“ELMS”) assets, including all IP and a 650,000-square-foot plant in Mishawaka, Indiana.

For more information about the company, visit www.MullenUSA.com.

NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN